Haematology Acute leukaemias Flashcards

(48 cards)

1
Q

Leukaemia Biology and General Features →

A

Clonal Proliferation of malignant blood cells derived from primitive haemopoitic stem cells in bone marrow. Uncontrolled expansion of hypofunctional cells in blood, bone marrow and other organs leads to suppression of normal haemopoiesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Main clinical problems include

A
  • Anaemia
  • Bleeding and susc/L with blast cells visible on the peipheral eptibility to infection
  • Lymphadenopathy
  • Hepatosplenomegaly
  • Skin and CNS infiltration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Acute Leukaemia types

A

Acute myeloid leukaemia (AML)

Acute lymphoblastic leukaemia (ALL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acute Leukaemia definition

A
  • Proliferation of primitive immature blast cells

* Rapid onset and progression if untreated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chronic Leukaemia types

A
  • Chronic myeloid leukaemia

* Chronic lymphocytic leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chronic Leukaemia definition

A
  • Proliferation of more mature precursor cells

* Slower progression and less aggressive course

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Aetiopathogenesis of Leukemia → Endogenous factors

A

Chromosome fragility syndromes
Downs syndrome
Hereditary immune deficiency
Familial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Aetiopathogenesis of Leukemia → Exogenous factors

A
Radiation
Chemotherapy
Benzene
Viral infection
Acquired immune deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aetiopathogenesis of Leukemia →

A
Haemopoeitic stem cell
Clonal initiation
Clonal expansion
Suppression of normal haemopoiesis
Clonal regression (expanding sub-clones)
Clinical leukaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

(AML) Target population

A

Commoner in adults (old age is very common)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

(AML) Incidence

A

1:10,000 annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

(AML) Frequency/Age distribution

A

Increases with age (median >70 yr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

(AML) Presentation

A

May be de novo or secondary to other haematological disorders e.g. myelodysplasia, myeloproliferative disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

(AML) Prognosis (brief)

A

Curable with potentially a near to normal life as before

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

(AML) Morphology

A

Lots of blasts in marrow

Primitive nuclei with a high Nuclei:Cytoplasm ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acute Promyelocytic Leukaemia with t (15;17) → Urgency

A

Urgent – this is a true haematological emergency

If you survive the first 48 hours – there I a good prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Acute Promyelocytic Leukaemia with t (15;17) → Pathophysiology

A

Granules released causing coagulopathy and potentially CNS ischemia = death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Acute Promyelocytic Leukaemia with t (15;17) → Major investigations

A

FBC
Bone marrow
Flow cytometry
Cytogenetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Acute Promyelocytic Leukaemia with t (15;17) → FBC shows

A

Low hB and platelet count
WBC usually 20-100 x 109/L
Blast cells visible on the peripheral blood film

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Acute Promyelocytic Leukaemia with t (15;17) → Bone marrow shows

A

Blasts >20% of nucleated cells

21
Q

Acute Promyelocytic Leukaemia with t (15;17) → Flow cytometry

A

CD+13, CD33+: Helpful to confirm AML

22
Q

Acute Promyelocytic Leukaemia with t (15;17) → Cytogenetics

A

Important prognostic indicator e.g. t(15;17), t(8;21), inv16 good.
Monosomy 7, abnormalities chromosome 5, complex cytogenetics (>5 abnormalities) poor prognosis.

23
Q

Acute Promyelocytic Leukaemia with t (15;17) → T (15,17) marker of

A

Good prognosis

24
Q

Acute Promyelocytic Leukaemia with t (15;17) →T (8,21) marker of

A

Poor prognosis (M2 type)

25
Acute Promyelocytic Leukaemia with t (15;17) → Monosomy 7, 5 marker of
Poor prognosis
26
Acute Promyelocytic Leukaemia with t (15;17) → Treatment
Combination chemotherapy • Important drugs include cytosine arabionoside and daumrubicin • Retinoic acid/ arsenic trioxide used in acute promyelocytic leukaemia – high dose ara-C important in optimising outcome. Supportive care • Transfusions of red cells and platelets • Antiseptic mouthwashes, clean diet • Oral prophylactic ant-fungal agents and antibiotics (ciprofloxacin) • Prompt iv antibiotic therapy for infections (broadspec)
27
Acute Promyelocytic Leukaemia with t (15;17) → Chemotherapy plan
3-4 cycles of therapy given 4-6 weekly | Treatment induces profound marrow suppression, prolonged pancytopenia
28
Acute Promyelocytic Leukaemia with t (15;17) → Emergency ATRA
Alltrans retinoic acid – matures cells and prevents granulocyte release
29
Acute Promyelocytic Leukaemia with t (15;17) → Complications of treatment
* Nfection: mainly bacterial and fungal * Bleeding (if in CNS can be fatal) * Debility, profound weight loss * Social: inpatient for most of 6 months, loss of employment, stress on family (in hospital 70-90% of he time)
30
AML Prognosis
Better if <10% of over 60 yrs and poor risk cytogenetics
31
AML Favourable cytogenetics
FLT3 negative and NMP1 positive
32
AML Poor risk cytogenetics
FLT3 positive
33
AML Allogenic bone marrow transplantation
If <50 yrs with HLA – matched donor, 50-70% cure rate. But risk of early transplanted-related mortality and graft versus host disease. Often used as salvage therapy in 2nd remission.
34
ALL Definition
Primitive lymphoblasts infiltrate bone marrow and circulate in blood, infiltrate liver and spleen.
35
ALLEpi
Commonest leukaemia in children: peak age 2-10 years. Another peak at >60
36
ALL Clinical features
Similar to AM but more frequently: 1. Lymphadenopathy 2. Hepatosplenomegaly and CNS involvement (meninges)
37
ALL Symptoms
Classic: bone pain Sweats LOW
38
ALL Investigations
* Lumbar puncture. As for AML. Important to determine if there is evidence of CNS disease (usually when peripheral blasts cleared) * Flow cytometry – may show blasts of B cell 9CD10+, CD 19+) or T cell lineage (20%) * Cytogenetics
39
ALL Cytogenetics
* Philadelphia chromosome t(9;22) seen in 20-25% of adults – poor prognostic marker but specific therapy with tyrosine kinase inhibitors * Other poor prognostic lesions t(4;11). T(8;14) and complex cytogenetics
40
ALL Morphology
• Common ALL: blast cells positive for CD10 on flow cytometry
41
ALL Treatment of ALL
* Chemotherapy with complex combinations of cytotoxic drugs e.g. steroids, vincristine, daunorubicin, asparginase. * Different drugs for second phase of induction
42
ALL Induction protocol
2 months. Remission induction
43
ALLConsolidation
4 month intensive chemotherapy and CNS prophylaxis (intra-thecal (4-6 injects) and methotrexate
44
ALL Maintenance
2 years therapy; mainly oral cytotoxic drugs
45
ALL ALL Prognosis
>80% cure in childhood ALL | Best prognosis if 1-10 years, female with low presenting WBC and no CNS disease (<35 mean a better prognosis
46
ALL Allogenic bone marrow transplant in 1st C.R considered
In adults and children with poor prognostic indicators (eg. Ph+ ALL) → 40% cure rate. Role in other patients controversial.
47
Minimum residual disease:
1. Leukaemia clone can be identified by DNA fingerprinting and accurately measured using Q PCR. Sensitive (2 in 10,000 cells or better) 2. Response to therapy after 2 months may override other pre-treatment prognostic factors 3. MRD used to decide treatment in children and adults. Remission testing via:
48
Remission testing via:
1. Morphological remission (cant see it on blood films) 2. Cytomorphology 3. FISH detection (1 in 100 cells are abnormal) 4. Immunophenotyope (1 in 10,000) 5. PCR detection